Related Experiment Video
Updated: Apr 5, 2026
07:51
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
12.9K
Clinical Decision Support to Implement CYP2D6 Drug-Gene Interaction.
Pedro J Caraballo1, Mark Parkulo1, David Blair1
1Mayo Clinic, Rochester, Minnesota, USA.
Studies in Health Technology and Informatics
|August 12, 2015
Summary
Pharmacogenomic testing predicts CYP2D6 enzyme activity. Integrating clinical decision support into electronic health records shows promise for preventing adverse drug events but faces implementation challenges.
Area of Science:
- Pharmacogenomics
- Clinical Informatics
- Drug Metabolism
Background:
- CYP2D6 enzyme activity influences drug metabolism and patient response.
- Adverse drug events are a significant concern in clinical practice.
- Pharmacogenomic testing offers a way to personalize drug therapy.
Purpose of the Study:
- To assess the feasibility of implementing clinical decision support (CDS) alerts for CYP2D6-metabolized drugs.
- To evaluate the potential of CDS to prevent adverse drug events.
- To identify challenges associated with integrating pharmacogenomic data and CDS into electronic health records (EHRs).
Main Methods:
- Pharmacogenomic testing was used to determine CYP2D6 metabolic activity levels.
- Clinical decision support alerts were integrated into the electronic health record system.
- The implementation's feasibility and associated challenges were evaluated based on initial findings.
Main Results:
- The integration of CDS alerts for CYP2D6 testing demonstrated high feasibility.
- Initial findings highlighted significant challenges in the implementation process.
- The study suggests a potential pathway for reducing adverse drug events related to CYP2D6 metabolism.
Conclusions:
- Clinical decision support integrated with pharmacogenomic testing is feasible for managing drugs metabolized by CYP2D6.
- Addressing identified challenges is crucial for successful widespread adoption.
- This approach holds potential for improving patient safety and preventing adverse drug reactions.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
199
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
199
01:27Pharmacogenetics of Drug Metabolism: Overview
125
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
125
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
114
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
114
01:29Pharmacogenomics: Identification of New Drug Targets
86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
01:25Pharmacokinetics: Drug–Drug Interactions
693
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
693
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69